Syntaxin

Syntaxin genetically engineered bacterial toxins to develop novel drugs that inhibit abnormal cell secretion, a key component of many diseases. The company was focused on the treatment of neurological, inflammatory and endocrine diseases. Syntaxin was formed as a spin-out from the UK Health Protection Agency in November 2005. The company was acquired by Ipsen in July 2013.